IL1B and myocardial infarction: Recently, the CanakinumabAnti-inflammatory Thrombosis Outcomes Study (CANTOS) showed that blockinginflammation with the anti-IL-1β monoclonal antibody canakinumab reducedheart attacks, strokes and new-onset diabetes among patients with priormyocardial infarction (MI) [8].